Registered Zambia · ZAMRA

STPase Injection

STREPTOKINASE 1500000IU 15 000 000 IU

113/108 Powder for Injection 15 000 000 IU INN generic

What it does

Streptokinase is a medication used to dissolve blood clots in certain medical conditions.

Commonly used for: heart attack (myocardial infarction), pulmonary embolism (lung blood clots), deep vein thrombosis (DVT)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
113/108
Registration date
2024-05-29
Expiry date
2029-05-28
Status
Registered/Compliant
Active ingredient
STREPTOKINASE 1500000IU 15 000 000 IU
Dosage form
Powder for Injection
Strength
15 000 000 IU
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Cadila Pharmaceuticals
Country of origin
India
Manufacturer location
Survey No 1389, Trasad, Road, Dholka, Gujarat 382225, India

Source: Zambia Medicines Regulatory Authority · fetched 2026-03-12 00:04:18 · updated 2026-09-24 03:36:16

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About this medicine

Streptokinase is a medication used to dissolve blood clots in certain medical conditions.

What it treats

  • heart attack (myocardial infarction)
  • pulmonary embolism (lung blood clots)
  • deep vein thrombosis (DVT)

How it works

Streptokinase helps break down clots by activating the body's natural clot-dissolving system.

Who it's for

This medication is typically used for adults experiencing severe blood clot-related issues.

Cautions

  • • Avoid using with other medications that thin the blood.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Streptokinase

BNF-referenced

Streptokinase is a thrombolytic agent derived from streptococci bacteria, used primarily to dissolve blood clots in various medical conditions, including acute myocardial infarction, pulmonary embolism, and certain types of thrombosis. It acts by converting plasminogen to plasmin, which then breaks down fibrin, the main component of blood clots. Streptokinase is typically administered intravenously under controlled conditions, particularly in emergency settings, to restore blood flow in occluded vessels.

Indications

  • Acute myocardial infarction
  • Pulmonary embolism
  • Deep-vein thrombosis
  • Central retinal venous or arterial thrombosis
  • Acute ischaemic stroke (under specialist supervision)

Dosage

Children: For children aged 12–17 years: Initially 250

Adults: Initially 10 mg by intravenous injection, followed by 90 mg as an intravenous infusion over 2 hours, with a maximum dose of 1.5 mg/kg for patients weighing less than 65 kg.

Mechanism of action

Streptokinase binds to plasminogen, converting it to plasmin, an enzyme that degrades fibrin in blood clots. This process enhances the fibrinolytic activity, leading to the dissolution of thrombi and restoration of blood flow. Streptokinase does not have a direct effect on the coagulation cascade but rather facilitates the natural fibrinolytic process.

Pharmacodynamics

The pharmacodynamic effects of streptokinase include its ability to reduce the size of thrombi and restore blood flow in vessels occluded by clots. Its efficacy is influenced by the timing of administration, with earlier treatment correlating with better outcomes. The agent's activity is also dependent on the presence of plasminogen and requires the formation of a streptokinase-plasminogen complex to initiate fibrinolysis.

Pharmacokinetics

Streptokinase is administered intravenously, leading to rapid distribution in the bloodstream. Its half-life is approximately 23 minutes, and it is mainly cleared through the reticuloendothelial system. The enzyme's activity diminishes rapidly after administration, necessitating careful monitoring and potentially repeated dosing. Individual patient factors, such as renal function, can affect the pharmacokinetics of streptokinase.

Contra-indications

  • Recent delivery
  • Cavernous pulmonary disease
  • Occlusive peripheral arterial disease
  • Severe cerebrovascular disease
  • Recent severe stroke
  • Septic thrombotic disease
  • Atrial fibrillation
  • Mitral valve defect

Adverse effects

  • Arrhythmias
  • Asthenia
  • Diarrhoea
  • Epigastric pain
  • Headache
  • Malaise
  • Pain
  • Brain oedema (caused by reperfusion)

Precautions

  • Use with caution in patients with renal failure and those at risk of bleeding

Pregnancy

Manufacturer advises caution; no specific data available.

Breast-feeding

Manufacturer advises avoiding use; no information available.

Storage

Store in a refrigerator (2 to 8 degrees Celsius). Protect from light.

Formulations

  • Powder for solution for injection
BNF 85 (British National Formulary) p.257 BNF for Children 2019-2020 p.112 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.